BIOLQ Quote, Financials, Valuation and Earnings

Milestone Scientific has a net margin of -13.16% compared to Biolase's net margin of -58.13%. Biolase's return on equity of -21668.17% beat Milestone Scientific's return on equity of -61.33%.

Biolase has a consensus price target of $1.2000, signalling upside risk potential of 21999.45%. On the other hand Milestone Scientific has an analysts' consensus of -- which suggests that it could grow by 123.68%. Given that Biolase has higher upside potential than Milestone Scientific, analysts believe Biolase is more attractive than Milestone Scientific.

Biolase has a beta of 0.690, which suggesting that the stock is 30.959% less volatile than S&P 500. In comparison Milestone Scientific has a beta of 1.096, suggesting its more volatile than the S&P 500 by 9.625%.

Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Milestone Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Milestone Scientific pays out -- of its earnings as a dividend.

Biolase quarterly revenues are $10.9M, which are larger than Milestone Scientific quarterly revenues of $2.5M. Biolase's net income of -$1.4M is higher than Milestone Scientific's net income of -$1.5M. Notably, Biolase's price-to-earnings ratio is -- while Milestone Scientific's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 8.39x for Milestone Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Envista Holdings has a net margin of -13.16% compared to Biolase's net margin of 1.36%. Biolase's return on equity of -21668.17% beat Envista Holdings's return on equity of -35.84%.

Biolase has a consensus price target of $1.2000, signalling upside risk potential of 21999.45%. On the other hand Envista Holdings has an analysts' consensus of $21.42 which suggests that it could grow by 12.1%. Given that Biolase has higher upside potential than Envista Holdings, analysts believe Biolase is more attractive than Envista Holdings.

Biolase has a beta of 0.690, which suggesting that the stock is 30.959% less volatile than S&P 500. In comparison Envista Holdings has a beta of 1.331, suggesting its more volatile than the S&P 500 by 33.125%.

Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Envista Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Envista Holdings pays out -- of its earnings as a dividend.

Biolase quarterly revenues are $10.9M, which are smaller than Envista Holdings quarterly revenues of $601M. Biolase's net income of -$1.4M is lower than Envista Holdings's net income of $8.2M. Notably, Biolase's price-to-earnings ratio is -- while Envista Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 1.31x for Envista Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Wellness Center USA has a net margin of -13.16% compared to Biolase's net margin of --. Biolase's return on equity of -21668.17% beat Wellness Center USA's return on equity of --.

Biolase has a consensus price target of $1.2000, signalling upside risk potential of 21999.45%. On the other hand Wellness Center USA has an analysts' consensus of -- which suggests that it could fall by --. Given that Biolase has higher upside potential than Wellness Center USA, analysts believe Biolase is more attractive than Wellness Center USA.

Biolase has a beta of 0.690, which suggesting that the stock is 30.959% less volatile than S&P 500. In comparison Wellness Center USA has a beta of 1.698, suggesting its more volatile than the S&P 500 by 69.833%.

Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Wellness Center USA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Wellness Center USA pays out -- of its earnings as a dividend.

Biolase quarterly revenues are $10.9M, which are larger than Wellness Center USA quarterly revenues of --. Biolase's net income of -$1.4M is higher than Wellness Center USA's net income of --. Notably, Biolase's price-to-earnings ratio is -- while Wellness Center USA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 0.16x for Wellness Center USA. Usually stocks with elevated PS ratios are considered overvalued.

Dentsply Sirona has a net margin of -13.16% compared to Biolase's net margin of -51.95%. Biolase's return on equity of -21668.17% beat Dentsply Sirona's return on equity of -13.34%.

Biolase has a consensus price target of $1.2000, signalling upside risk potential of 21999.45%. On the other hand Dentsply Sirona has an analysts' consensus of $23.11 which suggests that it could grow by 23.33%. Given that Biolase has higher upside potential than Dentsply Sirona, analysts believe Biolase is more attractive than Dentsply Sirona.

Biolase has a beta of 0.690, which suggesting that the stock is 30.959% less volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.960, suggesting its less volatile than the S&P 500 by 4.04%.

Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 3.44% to investors and pays a quarterly dividend of $0.16 per share. Biolase pays -- of its earnings as a dividend. Dentsply Sirona pays out -87.88% of its earnings as a dividend.

Biolase quarterly revenues are $10.9M, which are smaller than Dentsply Sirona quarterly revenues of $951M. Biolase's net income of -$1.4M is higher than Dentsply Sirona's net income of -$494M. Notably, Biolase's price-to-earnings ratio is -- while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 0.98x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.